Foghorn Therapeutics Presents New Preclinical Data on Selective Smarca2 Inhibitor Fhd-909 and Selective Cbp and Selective Ep300 Degrader Programs and Provides Pipeline Update

THOMSON REUTERS
29 Apr

Foghorn Therapeutics Presents New Preclinical Data on Selective Smarca2 Inhibitor Fhd-909 and Selective Cbp and Selective Ep300 Degrader Programs and Provides Pipeline Update

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10